Panitch H S
Research Service, VA Medical Center, Baltimore, MD.
Ann Neurol. 1994;36 Suppl(Suppl):S25-8. doi: 10.1002/ana.410360709.
Exacerbations of multiple sclerosis (MS) are triggered by exogenous events, the best documented being viral upper respiratory infections (URIs), which can stimulate secretion of cytokines such as interferon-gamma (IFN-gamma) by immune cells. In conjunction with a recent clinical trial of systemic interferon-beta (IFN-beta) in relapsing-remitting MS, we studied the occurrence of viral infections and their correlation with MS attacks. Thirty patients kept daily logs, noting URI symptoms in themselves, family members, and co-workers. Patients were examined every 3 months, or whenever an attack of MS occurred, and were tested for antibodies to common upper respiratory pathogens. A strong correlation was found between MS attacks and URIs. There were 168 URIs in 2,792 patient-weeks, including 996 weeks at risk (the interval beginning 1 week before and ending 5 weeks after onset of URI symptoms) and 1,796 weeks not at risk. Nearly two-thirds of attacks occurred in periods at risk. Attack rates were 2.92 per year in weeks at risk compared to 1.16 per year in weeks not at risk, a significant difference (p < 0.001). High-dose interferon reduced the frequency of MS attacks, but had no effect on the number of URIs. Although a specific virus could not be incriminated, we concluded that URIs of presumed viral origin are an important trigger of MS attacks, and that treatment with IFN-beta reduces the attack rate, but not by preventing URIs. Rather, it may modulate responses to viral infection that would otherwise lead to immune activation and clinical symptoms.
多发性硬化症(MS)的病情加重由外部事件引发,其中记录最详实的是病毒性上呼吸道感染(URIs),它可刺激免疫细胞分泌细胞因子,如干扰素-γ(IFN-γ)。结合近期一项针对复发缓解型MS的全身性干扰素-β(IFN-β)临床试验,我们研究了病毒感染的发生情况及其与MS发作的相关性。30名患者记录每日日志,记录自身、家庭成员及同事的URI症状。患者每3个月接受检查,或在MS发作时随时接受检查,并检测针对常见上呼吸道病原体的抗体。结果发现MS发作与URIs之间存在强烈相关性。在2792个患者周中有168次URIs,其中包括996个有风险周(从URI症状发作前1周开始至发作后5周结束的时间段)和1796个无风险周。近三分之二的发作发生在有风险时间段。有风险周的发作率为每年2.92次,而无风险周为每年1.16次,差异显著(p < 0.001)。高剂量干扰素降低了MS发作的频率,但对URIs的数量没有影响。尽管无法确定具体是哪种病毒,但我们得出结论,推测为病毒起源的URIs是MS发作的重要触发因素,且用IFN-β治疗可降低发作率,但并非通过预防URIs来实现。相反,它可能调节对病毒感染的反应,否则这些反应会导致免疫激活和临床症状。